OncoMatch/Clinical Trials/NCT05045950
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
Is NCT05045950 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Memantine -Twice Daily or Extended Release for brain metastases.
Treatment: Memantine -Twice Daily or Extended Release — Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: cranial whole brain radiation therapy
Prior cranial whole brain radiation therapy
Lab requirements
Kidney function
creatinine clearance is ≥ 30 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Froedtert Hospital & the Medical College of Wisconsin · Milwaukee, Wisconsin
- Clement J. Zablocki Veterans Affairs Medical Center · Milwaukee, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify